StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

Equities researchers at StockNews.com began coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued on Friday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on FGEN. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of FibroGen in a report on Thursday. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

Shares of FGEN stock opened at $0.71 on Friday. The stock’s 50-day simple moving average is $0.53 and its 200-day simple moving average is $0.43. The firm has a market capitalization of $71.13 million, a PE ratio of -0.57 and a beta of 0.75. FibroGen has a fifty-two week low of $0.18 and a fifty-two week high of $2.80.

Hedge Funds Weigh In On FibroGen

Hedge funds have recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new position in FibroGen during the fourth quarter worth approximately $27,000. Velan Capital Investment Management LP acquired a new position in shares of FibroGen during the fourth quarter valued at approximately $42,000. XTX Topco Ltd raised its holdings in shares of FibroGen by 423.8% during the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after acquiring an additional 77,693 shares during the last quarter. Franklin Street Advisors Inc. NC raised its holdings in shares of FibroGen by 100.0% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 100,000 shares during the last quarter. Finally, FMR LLC raised its holdings in shares of FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 68,569 shares during the last quarter. Hedge funds and other institutional investors own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.